Moreover, the phase 3 ETER701 trial demonstrated that the addition of the PD-L1 inhibitor TQB2450 and anlotinib to standard chemotherapy significantly improved the OS and PFS of patients with ES-SCLC [243]. Here, CD274 is linked to small cell lung carcinoma.